Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity - PubMed (original) (raw)
Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity
Mercedes B Fuertes et al. J Immunol. 2008.
Abstract
Most tumors grow in immunocompetent hosts despite expressing NKG2D ligands (NKG2DLs) such as the MHC class I chain-related genes A and B (MICA/B). However, their participation in tumor cell evasion is still not completely understood. Here we demonstrate that several human melanomas (cell lines and freshly isolated metastases) do not express MICA on the cell surface but have intracellular deposits of this NKG2DL. Susceptibility to NK cell-mediated cytotoxicity correlated with the ratio of NKG2DLs to HLA class I molecules but not with the amounts of MICA on the cell surface of tumor cells. Transfection-mediated overexpression of MICA restored cell surface expression and resulted in an increased in vitro cytotoxicity and IFN-gamma secretion by human NK cells. In xenografted nude mice, these melanomas exhibited a delayed growth and extensive in vivo apoptosis. Retardation of tumor growth was due to NK cell-mediated antitumor activity against MICA-transfected tumors, given that this effect was not observed in NK cell-depleted mice. Also, mouse NK cells killed MICA-overexpressing melanomas in vitro. A mechanistic analysis revealed the retention of MICA in the endoplasmic reticulum, an effect that was associated with accumulation of endoH-sensitive (immature) forms of MICA, retrograde transport to the cytoplasm, and degradation by the proteasome. Our study identifies a novel strategy developed by melanoma cells to evade NK cell-mediated immune surveillance based on the intracellular sequestration of immature forms of MICA in the endoplasmic reticulum. Furthermore, this tumor immune escape strategy can be overcome by gene therapy approaches aimed at overexpressing MICA on tumor cells.
Similar articles
- Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A. Schwinn N, et al. Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098. Int J Cancer. 2009. PMID: 19089914 - Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Pende D, et al. Cancer Res. 2002 Nov 1;62(21):6178-86. Cancer Res. 2002. PMID: 12414645 - MICA triggering signal for NK cell tumor lysis is counteracted by HLA-G1-mediated inhibitory signal.
Menier C, Riteau B, Carosella ED, Rouas-Freiss N. Menier C, et al. Int J Cancer. 2002 Jul 1;100(1):63-70. doi: 10.1002/ijc.10460. Int J Cancer. 2002. PMID: 12115588 - Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB, Domaica CI, Zwirner NW. Fuertes MB, et al. Front Immunol. 2021 Jul 29;12:713158. doi: 10.3389/fimmu.2021.713158. eCollection 2021. Front Immunol. 2021. PMID: 34394116 Free PMC article. Review. - Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E, Vassena L, Cerboni C, Doria M. Giuliani E, et al. Curr Drug Targets. 2016;17(1):54-64. doi: 10.2174/1389450116666150630110329. Curr Drug Targets. 2016. PMID: 26122035 Review.
Cited by
- Human NK cells and cancer.
Cantoni C, Falco M, Vitale M, Pietra G, Munari E, Pende D, Mingari MC, Sivori S, Moretta L. Cantoni C, et al. Oncoimmunology. 2024 Jul 16;13(1):2378520. doi: 10.1080/2162402X.2024.2378520. eCollection 2024. Oncoimmunology. 2024. PMID: 39022338 Free PMC article. Review. - The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer.
Tan G, Spillane KM, Maher J. Tan G, et al. Biology (Basel). 2023 Aug 2;12(8):1079. doi: 10.3390/biology12081079. Biology (Basel). 2023. PMID: 37626965 Free PMC article. Review. - SUMOylation and related post-translational modifications in natural killer cell anti-cancer responses.
Molfetta R, Petillo S, Cippitelli M, Paolini R. Molfetta R, et al. Front Cell Dev Biol. 2023 May 25;11:1213114. doi: 10.3389/fcell.2023.1213114. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37313439 Free PMC article. Review. - The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology.
Secchiari F, Nuñez SY, Sierra JM, Ziblat A, Regge MV, Raffo Iraolagoitia XL, Rovegno A, Ameri C, Secin FP, Richards N, Ríos Pita H, Vitagliano G, Rico L, Mieggi M, Frascheri F, Bonanno N, Blas L, Trotta A, Friedrich AD, Fuertes MB, Domaica CI, Zwirner NW. Secchiari F, et al. Oncoimmunology. 2022 Aug 3;11(1):2104991. doi: 10.1080/2162402X.2022.2104991. eCollection 2022. Oncoimmunology. 2022. PMID: 35936986 Free PMC article. - Cytokine-induced killer cells mediated pathways in the treatment of colorectal cancer.
Fayyaz F, Yazdanpanah N, Rezaei N. Fayyaz F, et al. Cell Commun Signal. 2022 Mar 28;20(1):41. doi: 10.1186/s12964-022-00836-0. Cell Commun Signal. 2022. PMID: 35346234 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials